Caprini Vte Score Calculator
Assess venous thromboembolism risk in surgical patients using the Caprini scoring system. Enter values for instant results with step-by-step formulas.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist
Medical disclaimer: This calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are general estimates and may not reflect your individual circumstances. Always consult a qualified healthcare professional before making decisions about your health.
Formula
Caprini Score = Sum of weighted risk factors (1, 2, 3, or 5 points each)
The Caprini score assigns weighted points to approximately 40 risk factors: 1 point for minor factors (age 41-60, BMI > 25, varicose veins), 2 points for moderate factors (age 61-74, major surgery > 45 min, malignancy), 3 points for significant factors (age >= 75, prior VTE, thrombophilia), and 5 points for major factors (stroke, arthroplasty, spinal cord injury). Total score determines VTE risk category and prophylaxis intensity.
Worked Examples
Example 1: Moderate Risk General Surgery Patient
Problem:A 55-year-old woman (BMI 28) is scheduled for elective laparoscopic cholecystectomy expected to last 60 minutes. She has varicose veins and takes oral contraceptives. No history of VTE.
Solution:Caprini Score: Age 41-60: 1 point BMI > 25: 1 point Varicose veins: 1 point Oral contraceptives: 1 point Laparoscopic surgery > 45 min: 2 points Total = 6 points Risk Category: High Risk VTE incidence: 6.5 - 11.3%
Result:Score 6 (High Risk) | VTE risk 6.5-11.3% | LMWH + IPC recommended
Example 2: High Risk Orthopedic Surgery Patient
Problem:A 76-year-old man is undergoing total hip arthroplasty. He has a history of DVT 3 years ago and is heterozygous for Factor V Leiden mutation. He also has a history of CHF.
Solution:Caprini Score: Age >= 75: 3 points Elective hip arthroplasty: 5 points Prior DVT: 3 points Factor V Leiden: 3 points CHF (< 1 month): 1 point Total = 15 points Risk Category: High Risk VTE incidence: >11.3% without prophylaxis
Result:Score 15 (High Risk) | LMWH/DOAC + IPC + 35 days extended prophylaxis
Frequently Asked Questions
What is the Caprini score and what does it assess?
The Caprini score is a validated risk assessment model (RAM) developed by Dr. Joseph Caprini that estimates a surgical patient's risk of developing venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). The score assigns weighted points to approximately 40 individual risk factors organized into four tiers: 1-point factors, 2-point factors, 3-point factors, and 5-point factors. These risk factors encompass patient demographics (age), surgical factors (type and duration), medical comorbidities, mobility status, thrombophilia states, and prior VTE history. The cumulative score stratifies patients into lowest, low, moderate, and high VTE risk categories, guiding decisions about the type and duration of thromboprophylaxis. The Caprini model has been validated in over 250,000 surgical patients.
How is the Caprini score used to guide VTE prophylaxis decisions?
The Caprini score translates directly into specific prophylaxis recommendations based on the risk tier. Patients with a score of 0 (lowest risk, VTE incidence less than 0.5 percent) require only early ambulation. Scores of 1 to 2 (low risk, VTE incidence 0.7 to 1.8 percent) warrant mechanical prophylaxis with intermittent pneumatic compression (IPC) devices or graduated compression stockings. Scores of 3 to 4 (moderate risk, VTE incidence 2.0 to 6.3 percent) indicate pharmacological prophylaxis with low-molecular-weight heparin (LMWH), low-dose unfractionated heparin (UFH), or fondaparinux, combined with mechanical prophylaxis. Scores of 5 or higher (high risk, VTE incidence 6.5 to 11.3 percent) require aggressive pharmacological prophylaxis combined with mechanical measures, and extended-duration prophylaxis (up to 30 days) should be considered, particularly for cancer surgery and major orthopedic procedures.
Why are thrombophilia states assigned 3 points in the Caprini scoring system?
Inherited and acquired thrombophilias receive 3 points each in the Caprini score because they represent significant, independent risk factors for venous thromboembolism that persist throughout the perioperative period and beyond. Factor V Leiden mutation increases VTE risk 3 to 8 times in heterozygotes and 50 to 80 times in homozygotes. The prothrombin 20210A mutation increases risk 2 to 5 fold. Antiphospholipid antibodies (lupus anticoagulant and anticardiolipin antibodies) are associated with a 2 to 10 fold increase in VTE risk. Elevated homocysteine levels increase risk 2 to 3 fold. When these inherited or acquired hypercoagulable states combine with the transient hypercoagulability of surgery (tissue factor release, immobilization, venous stasis), the cumulative VTE risk becomes substantially elevated, justifying the high point assignment and the need for aggressive prophylaxis.
What pharmacological agents are used for VTE prophylaxis in surgical patients?
Several pharmacological agents are approved and recommended for VTE prophylaxis in surgical patients. Low-molecular-weight heparins (LMWH) such as enoxaparin (40 mg subcutaneously once daily) and dalteparin (5000 IU subcutaneously once daily) are the most commonly used agents due to their predictable pharmacokinetics, once-daily dosing, and favorable safety profile. Low-dose unfractionated heparin (UFH) at 5000 units subcutaneously every 8 to 12 hours is an alternative, particularly in patients with renal insufficiency. Fondaparinux (2.5 mg subcutaneously once daily) is a synthetic Factor Xa inhibitor used when heparin-induced thrombocytopenia is a concern. Direct oral anticoagulants (DOACs) including rivaroxaban, apixaban, and dabigatran are increasingly used for extended prophylaxis after major orthopedic surgery. Aspirin alone may be considered for lower-risk joint arthroplasty patients according to some guideline updates.
What is the evidence base for extended VTE prophylaxis after surgery?
Extended VTE prophylaxis beyond the hospital stay is supported by strong evidence for specific high-risk surgical populations. The ENOXACAN II trial demonstrated that 28 days of enoxaparin after cancer surgery reduced VTE by 60 percent compared to standard 6 to 10 day prophylaxis. Multiple randomized trials (RECORD 1-4 for rivaroxaban, ADVANCE 1-3 for apixaban, RE-MODEL and RE-NOVATE for dabigatran) showed that 28 to 35 days of prophylaxis after total hip and knee arthroplasty significantly reduced symptomatic VTE and asymptomatic DVT compared to shorter courses. The Ninth ACCP Guidelines recommend extended prophylaxis for 28 to 35 days after hip arthroplasty, hip fracture surgery, and major cancer surgery. For general and abdominal-pelvic surgery with Caprini scores of 5 or higher, extended prophylaxis is recommended when bleeding risk is acceptable.
How does cancer increase VTE risk and affect Caprini score interpretation?
Cancer significantly increases VTE risk through multiple prothrombotic mechanisms, and malignancy (present or previous) receives 2 points in the Caprini score. Cancer promotes thrombosis through direct activation of the coagulation cascade by tumor-produced tissue factor and cancer procoagulant, through tumor compression of blood vessels causing venous stasis, through chemotherapy-induced endothelial damage and vascular injury, through central venous catheters used for treatment, and through cancer-related immobility and deconditioning. The risk varies by cancer type: pancreatic, brain, gastric, and ovarian cancers carry the highest VTE rates (10 to 20 percent annually). Cancer patients undergoing surgery have 2 to 3 times higher VTE rates than non-cancer patients having the same procedure. Extended prophylaxis for 4 weeks postoperatively is strongly recommended for cancer patients undergoing major abdominal or pelvic surgery.
What are the contraindications to pharmacological VTE prophylaxis?
Pharmacological VTE prophylaxis is contraindicated in several clinical scenarios where the bleeding risk outweighs the thrombotic benefit. Absolute contraindications include active major bleeding, severe uncontrolled hypertension (systolic greater than 180 mmHg), thrombocytopenia (platelets less than 50,000), known heparin-induced thrombocytopenia (for heparin products), intracranial hemorrhage within 24 hours, and spinal or epidural hematoma risk in patients with neuraxial anesthesia. Relative contraindications include coagulopathy (INR greater than 1.5), hepatic failure with coagulopathy, concurrent use of antiplatelet agents, recent surgery with high bleeding risk (such as neurosurgery within 24 hours), and severe renal insufficiency (for LMWH and fondaparinux). When pharmacological prophylaxis is contraindicated, mechanical prophylaxis with intermittent pneumatic compression devices becomes the primary prevention strategy.
How do mechanical prophylaxis devices prevent VTE?
Mechanical prophylaxis devices prevent VTE through two complementary mechanisms: augmentation of venous blood flow to prevent stasis and stimulation of endogenous fibrinolytic activity. Intermittent pneumatic compression (IPC) devices apply cyclical external pressure to the legs through inflatable sleeves, compressing the calf and sometimes thigh veins to increase venous flow velocity by 200 to 300 percent above baseline, mimicking the hemodynamic effects of walking. This increased flow prevents venous stasis, one of the three elements of the Virchow triad. Studies have also shown that IPC devices stimulate the release of tissue plasminogen activator (tPA) from the venous endothelium, enhancing local fibrinolysis and preventing thrombus formation. Graduated compression stockings (GCS) provide continuous passive compression, greatest at the ankle and decreasing proximally, promoting venous return. When used alone, IPC devices reduce VTE by approximately 60 percent, but combining them with pharmacological prophylaxis provides additive protection.
What is the role of the Caprini score in non-surgical patients?
While the Caprini score was originally developed and validated for surgical patients, there have been efforts to adapt and apply it to non-surgical hospitalized medical patients. However, the Caprini score is not the standard risk assessment tool for medical patients. For medical patients, the Padua Prediction Score and the IMPROVE VTE risk score are more commonly used and better validated. The Padua score evaluates 11 risk factors including active cancer, previous VTE, reduced mobility, known thrombophilia, recent trauma or surgery, age 70 or older, heart or respiratory failure, acute MI or ischemic stroke, acute infection or rheumatologic disorder, obesity, and ongoing hormonal treatment. A Padua score of 4 or higher identifies medical patients at high risk who benefit from pharmacological prophylaxis. Using the Caprini score for medical patients may misclassify risk because the surgical risk factors that drive much of the Caprini scoring are absent.
How should VTE prophylaxis be managed around neuraxial anesthesia?
Management of VTE prophylaxis around neuraxial anesthesia (spinal or epidural) requires careful timing to prevent spinal or epidural hematoma, a rare but catastrophic complication. The American Society of Regional Anesthesia (ASRA) provides specific timing guidelines based on the anticoagulant used. For LMWH prophylactic dosing, the last dose should be given at least 12 hours before needle placement or catheter removal, and the next dose should be given at least 4 hours after. For therapeutic LMWH dosing, 24 hours must elapse before neuraxial procedures. For UFH, wait at least 4 to 6 hours after the last dose and check aPTT or anti-Xa levels if the patient has received UFH for more than 4 days. For fondaparinux, at least 36 to 42 hours must elapse. Direct oral anticoagulants require 3 to 5 half-lives of washout. Indwelling epidural catheters should not be removed until the appropriate interval has passed since the last anticoagulant dose.
References
Background & Theory
History
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist ยท Editorial policy
Related Calculators
๐งฎChads2 Score Calculator
Calculate the CHADS2 stroke risk score for patients with non-valvular atrial fibrillation.
๐งฎCha2ds2-Vasc Score Calculator
Calculate CHA2DS2-VASc score for stroke risk stratification in atrial fibrillation patients.
๐งฎHas-Bled Score Calculator
Assess bleeding risk in patients on anticoagulation using the HAS-BLED scoring system.
๐งฎHEART Score Calculator for Chest Pain Risk
Risk-stratify emergency department patients with chest pain using the HEART score.
๐งฎTIMI Risk Score Calculator
Calculate the TIMI risk score for STEMI and UA/NSTEMI patients.
๐งฎWells Score Dvt Calculator
Estimate pre-test probability of deep vein thrombosis using the Wells clinical criteria.